NCT04631757Unknown2 期
A Prospective, Non-randomized, Phase II Study of Camrelizumab in Combination With Concurrent Chemoradiotherapy for Initial Unresectable Proximal Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma Conversion Therapy
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 入组人数
- 33
- 主要终点
- 1-year progression-free survival (PFS) rate according to RECIST 1.1 base on investigator assessment
研究概览
简要总结
This is a study of Camrelizumab in Combination With concurrent radiotherapy and SOX for Initial Unresectable or potentially resectable proximal Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma. Patients without prior palliative therapy will be treated with Camrelizumab, radiotherapy (total 45 Gy), Oxaliplatin, and S-1. The primary endpoint is the 1-year PFS rate.
详细描述
The purpose of this study is to evaluate the efficacy and safety of Camrelizumab plus Concomitant Chemoradiotherapy in patients with Initial Unresectable or potentially resectable proximal Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma. 33 participants with Initial Unresectable locally advanced proximal gastric carcinoma /Gastroesophageal Junction (GEJ) Adenocarcinoma (Siewert type II/III) will be treated with conversion therapy as below once recruited:
- induction chemotherapy (3w): one cycle of camrelizumab 200mg q3w and SOX regimen (oxaliplatin 130mg/m2, d1, Q3w + S-1 40-60mg bid, d1-d14,Q3w);
- after the induction, concurrent Chemoradiotherapy will be started (5-6w): intensity modulated radiotherapy was given for tumors and high-risk lymphatic drainage areas, total dose:45Gy/25d, 1.8Gy/d, camrelizumab 200mg q3w, S-1 40-60mg bid, d1-d14, Q3w. The resectability assessment will be performed followed by MDT.
- Participants still unresectable will receive additional conversion therapy with camrelizumab and SOX regimen. The resectability will be evaluated every 6 weeks until resectable or up to 8 cycles of conversion therapy.
Resectable patients will receive D2 resection.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients who provided written informed consent to be subjects in this trial.
- •18-75 years old.
- •Has histologically-confirmed diagnosis of locally advanced unresectable or metastatic gastric or GEJ adenocarcinoma.
- •The initial unresectable or potentially resectable locally advanced proximal gastric carcinoma /Gastroesophageal Junction (GEJ) Adenocarcinoma (Siewert type II/III) in clinical stage T3-4N+M0 (AJCC 8 edition TNM stage) under any following condition: serious primary tumor invasion, unresectable bulky lymph node, retroperitoneal lymph node metastasis (RPLM). Clinical staging was performed according to enhanced CT/MRI examination.
- •No prior systemic chemotherapy for the treatment of the participant's advanced or metastatic disease (include but not limited to surgery, radiotherapy, chemotherapy, targeted therapy, immunotherapy)
- •Plan to have surgery after conversion therapy.
- •Patients capable of taking oral medication.
- •Performance status of 0 to 1 on the Eastern Cooperative Oncology Group (ECOG) Performance Scale.
- •Survival expectation ≥12 months.
- •Adequate organ function according to the following laboratory test results: absolute neutrophil count (ANC) ≥1.5×109/L; platelets ≥80×109/L; hemoglobin ≥90g/L; total bilirubin ≤1.5 ULN; serum creatinine ≤1.5 ULN or measured or calculated creatinine clearance > 50ml/min.
- •Female subjects of childbearing potential must have a negative urine or serum pregnancy test within 72 hours prior to receiving the first dose of study medication and must be willing to use an adequate method of contraception for the course of the study through 90 days after the last dose of study medication. Male subjects of childbearing potential must agree to use an adequate method of contraception starting with the first dose of study therapy through 90 days after the last dose of study therapy.
排除标准
- •HER2 positive subjects will be excluded.
- •With evidence of abdominal metastases.
- •Has a known additional malignancy that is progressing within the past 5 years. Note: Participants with basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or carcinoma in situ that have undergone potentially curative therapy are not excluded.
- •The presence of any of the following cardiac clinical symptoms or diseases: New York Heart Association (NYHA) congestive heart failure of grade II or above, LVEF<50%, unstable angina pectoris, myocardial infarction within the past 12 months, QTc ≥ 450ms for male, QTc ≥ 450ms for female, electrocardiogram (ECG) examination revealed clinically significant abnormalities, have factors that increase the risk of prolonged QTc and abnormal heart rhythm.
- •With active infection requiring drug intervention (e.g. anti-bacterial drugs, antiviral drugs, antifungal drugs treatment).
- •Patients with active hepatitis B (HBsAg positive and HBV DNA≥500 IU/ml), hepatitis C (HCV antibodies positive and HCV RNA copies > ULN)
- •With congenital immune deficiency or human immunodeficiency virus (HIV) infection.
- •Plan to receive or have previously received an organ or allogeneic bone marrow transplant.
- •Objective evidence of previous or current pulmonary fibrosis history, interstitial pneumonia, pneumoconiosis, radiation pneumonitis, drug-related pneumonia, pulmonary function damaged seriously etc; active tuberculosis (TB).
- •Patients with concurrent autoimmune disease, or a history of chronic or recurrent autoimmune disease.
- •Who has received immunosuppressants/systemic corticosteroids therapy < 7 days before the first dose for an immunosuppression purpose (> 10mg/day prednisone or other equivalency drugs).
- •Has received a live vaccine within 28 days prior to the first dose, plan to receive a live vaccine during or within 60 days after study treatment.
- •Have any contraindications for study treatment.
- •Participate in other clinical trials within 4 weeks before the first dose.
- •Is pregnant or breastfeeding.
- •Patients were judged unsuitable as subjects of this trial by investigators.
研究组 & 干预措施
Camrelizumab plus Chemoradiotherapy
Experimental
Patients with initial unresectable proximal gastric or gastroesophageal junction (GEJ) adenocarcinoma will receive camrelizumab 200mg q3w, SOX regimen (oxaliplatin 130mg/m2, d1, Q3w + S-1 40-60mg bid, d1-d14, Q3w), and intensity modulated radiotherapy for tumors and high-risk lymphatic drainage areas (45Gy/25d). Resectable patients after conversion therapy will receive D2 resection.
干预措施: Camrelizumab + SOX + Radiotherapy (Drug)
结局指标
主要结局
1-year progression-free survival (PFS) rate according to RECIST 1.1 base on investigator assessment
时间窗: Up to approximately 12 months
PFS was defined as the time from the first dose to the first documented disease progression per RECIST 1.1 based on investigator assessment. PFS rate at 1 year as estimated by Kaplan-Meier method.
次要结局
- progression-free survival (PFS) according to RECIST 1.1 base on investigator assessment(Up to approximately 36 months)
- Major pathological response（MPR）(Up to 30 days post-sugery)
- Overall Survival (OS)(Up to 5 years)
- disease-free survival (DFS) Per RECIST 1.1 base on investigator assessment(Up to approximately 36 months)
- Pathological Complete Response (pCR)(Up to 30 days post-sugery)
- rate of R0-resections(Up to 30 days post-sugery)
- Percentage of Participants Experiencing An Adverse Event (AEs)(Up to approximately12 months)
研究者
相似试验
尚未招募
2 期
Synchronous or Sequential Radiotherapy for Advanced Esophageal Squamous Cell Carcinoma With Oligometastases.Advanced Esophageal Squamous Carcinoma With OligometastasesNCT06143722West China Hospital63
招募中
2 期
Carbon-Ion Radiotherapy Plus Camrelizumab for Locally Recurrent Nasopharyngeal CarcinomaNasopharyngeal CarcinomaNCT04143984Shanghai Proton and Heavy Ion Center146
Unknown
不适用
Combination of Hyperfractionated Radiotherapy With Immunotherapy in Massive TumorsImmunotherapySBRTBulky TumorNCT04587817Peking University First Hospital60
Unknown
2 期
Induction Chemotherapy Combined With Camrelizumab in Locoregionally Advanced Hypopharyngeal CancerHypopharyngeal CancerImmunotherapyInduction ChemotherapyNCT04539600Sun Yat-sen University23
Unknown
2 期
Phase II Study for Combination of Camrelizumab and SBRT in the First-line Treatment for R/M HNSCCHead and Neck Squamous Cell CarcinomaNCT04399785Xingchen Peng34